LONDON/COPENHAGEN (Reuters) -Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...

The e-vehicle maker's quarterly delivery figures are expected early Wednesday. Shares shed about 1% ahead of the open. The ...

Novo Holdings CEO Kasim Kutay says China has "really moved up the value chain" in healthcare. "We've seen many others ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly’s weight-loss drug. This comes after ...

Novo Resources will launch a 2000m reverse circulation drilling program this month at Tibooburra in northwestern NSW to test ...

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...